{"ticker": {"uuid": "e36bc96e-1037-45f0-b9d6-1eea488c7371", "symbol": "EVGN", "name": "Evogene", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVUVvekVCd3Jxb2ZFZDlaeG1WT19RQm9hMTdHYW1aVHZVR3ZGV2pGbENZZmhmMDU2cEF5aWZ4VXFYWFpwQThKTVBRR0Y4cW56bDB3V19ZMWNvZFlSUFJocnNiNklDaWx3UEF2S21uT05yRVJOdzllamQ0anhMTEdYc3NiTlpaLTZGZG53Sms1d3VjTm9OcmI3TFVWbTRsQ0xGRklHOGFFLUQ1SnNuZ3FHd3E3LW0yeU45?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:06:17+00:00", "published_display": "17 Jul 2026 20:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOMWJEcjRackctZVNtY3pma2xsZ3RTXzgxWW8tbjJGdTNqWDA3VlYtUFFMdWctOWFPOVZ2Um9QVWJCSWJQd1VoYWxoc1JsY3pjc1hjLTFpMnNsRUxiVTNhYmZSeHZuakc4MWdKeVpMd2FiaUhiaXlHcEY0anBpODVEODVIQ0RzSUFvRlpaVTFPNm1sSkpxQWVObGpoU1ZnUGpIOXFmZGQ0SGRraGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:03:43+00:00", "published_display": "17 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities", "summary": "AgPlenus, a subsidiary of Evogene Ltd., has introduced its Antifungal Potency Predictor (APP), a machine learning model designed to forecast the antifungal potency of small molecules from their chemical structures. This AI tool expands Evogene's ChemPass AI for Ag\u2122 platform, enab", "url": "https://igrownews.com/agplenus-latest-news/", "source_name": "iGrow News", "published_at": "2026-07-16T21:42:13", "published_display": "16 Jul 2026 21:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AgPlenus AI Predicts Fungicide Potency Before Synthesis", "summary": "AgPlenus, a subsidiary of Evogene (NASDAQ: EVGN), has launched its Antifungal Potency Predictor (APP), a new machine learning model designed to forecast the antifungal potency of small molecules directly from their chemical structure. This expansion of the ChemPass AI for Ag\u2122 pla", "url": "https://www.stocktitan.net/news/EVGN/ag-plenus-launches-novel-ai-model-for-predicting-antifungal-potency-yuyrduwfmh4l.html", "source_name": "Stock Titan", "published_at": "2026-07-15T16:41:47", "published_display": "15 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag\u2122 Capabilities", "summary": "AgPlenus, a subsidiary of Evogene, announced the launch of its Antifungal Potency Predictor (APP), a new AI model designed to forecast the antifungal potency of small molecules earlier in the discovery process. This expansion amplifies the capabilities of Evogene's ChemPass AI fo", "url": "https://www.prnewswire.com/news-releases/agplenus-launches-novel-ai-model-for-predicting-antifungal-potency-expanding-chempass-ai-for-ag-capabilities-302826355.html", "source_name": "PR Newswire", "published_at": "2026-07-15T11:12:53", "published_display": "15 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake", "summary": "Kfir Silberman, through L.I.A. Pure Capital Ltd., has disclosed a 12.61% stake in Evogene Ltd. and is pushing for significant board changes. He has requested a special shareholder meeting to remove current board members (except Mr. Ofer Haviv), elect his nominees, and approve the", "url": "https://www.tradingview.com/news/tradingview:ca108cd6126e9:0-kfir-silberman-pushes-for-board-changes-at-evogene-with-12-61-stake/", "source_name": "TradingView", "published_at": "2026-07-10T13:40:28", "published_display": "10 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes", "summary": "Two Evogene Ltd. shareholders, L.I.A. Pure Capital Ltd. (12.61% stake) and Invest Pro Shukai Hon Ltd. (4.13% stake), are pushing for significant changes to Evogene's board of directors. They have formally demanded a special general meeting to remove most current directors, elect ", "url": "https://www.stocktitan.net/sec-filings/EVGN/schedule-13d-evogene-ltd-major-shareholder-acquisition-5-a7172c63292f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T13:40:24", "published_display": "10 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Partners with Tel Aviv University on AI Drug...", "summary": "Evogene, a computational chemistry company, is partnering with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to accelerate small-molecule drug discovery using Evogene's ChemPass AI platform. This collaboration, facilitated by Ramot, will combine AI-driven desig", "url": "https://allsci.com/news/licensing-deals/evogene-pairs-chempass-ai-with-tel-aviv-university-to-accelerate-academic-drug-discovery-pipeline/", "source_name": "AllSci", "published_at": "2026-07-09T15:09:09", "published_display": "09 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University launch drug discovery initiative", "summary": "Evogene and Tel Aviv University\u2019s Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate small-molecule drug discovery from Israeli academic research. The collaboration aims to overcome obstacles in early-stage drug development by combining Evogene's AI-based com", "url": "https://www.pharmaceutical-business-review.com/news/evogene-tel-aviv-university-drug-discovery/", "source_name": "Pharmaceutical Business review -", "published_at": "2026-07-09T09:41:13", "published_display": "09 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic biological insights and viable drug development program", "url": "https://www.sahmcapital.com/news/content/evogene-and-tel-aviv-universitys-blavatnik-center-for-drug-discovery-announce-joint-initiative-to-accelerate-ai-driven-small-molecule-drug-discovery-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-09T04:12:33", "published_display": "09 Jul 2026 04:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery", "summary": "Evogene Ltd. and the Blavatnik Center for Drug Discovery at Tel Aviv University have partnered in a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic research and drug candidate development by combin", "url": "https://www.marketscreener.com/news/evogene-ltd-and-blavatnik-center-for-drug-discovery-at-tel-aviv-university-announce-joint-initiativ-ce7f5ed9da8cf72d", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T16:40:21", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate AI-driven small-molecule drug discovery. This strategic initiative combines BCDD's experimental infrastructure with Evogene's ChemPass AI\u2122 generative engine to bridge the gap", "url": "https://www.biospectrumasia.com/news/34/27978/evogene-and-tel-aviv-university-to-accelerate-ai-driven-small-molecule-drug-discovery.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-08T13:50:31", "published_display": "08 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene partners with Tel Aviv University center on drug discovery", "summary": "Evogene Ltd. is collaborating with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to support small-molecule drug discovery projects from Israeli academic institutions. The partnership will combine Evogene\u2019s ChemPass AI computational chemistry platform with BCDD\u2019", "url": "https://www.investing.com/news/company-news/evogene-partners-with-tel-aviv-university-center-on-drug-discovery-93CH-4781318", "source_name": "Investing.com", "published_at": "2026-07-08T11:39:30", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University team up to speed small-molecule drug discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The collaboration will integrate Evogene's ChemPass AI\u2122 platform with BCDD's experimental infrastructure under a Design-M", "url": "https://www.stocktitan.net/news/EVGN/evogene-and-tel-aviv-university-s-blavatnik-center-for-drug-itv9ae3rd68p.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Evogene is changing the future for the pharma and agriculture markets", "summary": "Evogene, a company founded in 2002, is leveraging its AI-driven computational platform, ChemPass AI\u2122, to revolutionize small molecule discovery for pharmaceutical and agricultural markets. By integrating AI, computational chemistry, biology, and data science, Evogene aims to acce", "url": "https://www.jpost.com/business-and-innovation/article-901580", "source_name": "The Jerusalem Post", "published_at": "2026-07-06T08:41:38", "published_display": "06 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene | 6-K: Report of foreign private issuer (related to financial reporting)", "summary": "This article is a 6-K filing by Evogene, which is a report for a foreign private issuer. These filings typically relate to financial reporting and other material information that needs to be disclosed to the SEC. Without the actual document, specific details are unavailable, but ", "url": "https://www.moomoo.com/news/notice/307351118/evogene-6-k-report-of-foreign-private-issuer-related-to", "source_name": "Moomoo", "published_at": "2026-06-26T23:39:35", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Evogene Ltd. \u2013 NASDAQ:EVGN", "summary": "This page displays the \"Price to book forward\" metric for Evogene Ltd. (NASDAQ: EVGN) on the TradingView platform. The content primarily shows navigation elements and general information about TradingView's offerings, but the specific financial data for EVGN is not visible.", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:17", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Evogene Ltd. \u2013 NASDAQ:EVGN", "summary": "This article displays the forward enterprise value to revenue for Evogene Ltd. (NASDAQ: EVGN). It is a financial data point presented by TradingView, with additional information provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:52", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd Actuals & Estimates (NASDAQ:EVGN)", "summary": "This article provides comprehensive financial data and analyst estimates for Evogene Ltd. (NASDAQ:EVGN), including its current stock price, historical performance, analyst forecasts, and detailed financial statements. It also covers Q3 earnings, revenue, net income, market capita", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:09:52", "published_display": "25 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization", "summary": "Evogene Ltd. and Google Cloud have achieved a significant milestone in their collaboration, integrating agentic computational systems into Evogene's ChemPass AI platform. This advancement aims to accelerate small-molecule discovery and optimization by enabling early identificatio", "url": "https://www.marketscreener.com/news/evogene-ltd-and-google-cloud-announces-major-milestone-in-collaboration-advancing-chempass-ai-towar-ce7f5fd8df8df124", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T09:09:52", "published_display": "25 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI\u2122 Toward Autonomous Small Molecule Discovery and Optimization", "summary": "Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI\u2122 platform. This advancement aims to accelerate small-molecule discovery by enabling earlier identification of critical success criteria, ther", "url": "https://www.prnewswire.com/news-releases/evogene-announces-major-milestone-in-its-collaboration-with-google-cloud-advancing-chempass-ai-toward-autonomous-small-molecule-discovery-and-optimization-302808856.html", "source_name": "PR Newswire", "published_at": "2026-06-24T11:39:36", "published_display": "24 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene says Google Cloud AI can screen drug candidates earlier", "summary": "Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI\u2122 platform to enable earlier and deeper Target Product Profile (TPP) profiling for small-molecule discovery. This advancement aims to accelera", "url": "https://www.stocktitan.net/news/EVGN/evogene-announces-major-milestone-in-its-collaboration-with-google-h5guqfudklqg.html", "source_name": "Stock Titan", "published_at": "2026-06-24T02:10:39", "published_display": "24 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evogene Ltd (EVGN), highlighting major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in their positio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evgn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:00", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts project an average price target of $2.50, with one analyst recommending a \"Buy\" rating. The company's expected revenue for the next quarter is $3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:40:00", "published_display": "17 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy", "summary": "Evogene (EVGN) outlined its ChemPass AI platform, which leverages generative AI to discover and optimize small molecules for both pharmaceutical and agricultural applications. The platform's tools, PointHit, ActiveSearch, and LeadOpGPT, are designed to screen vast molecular libra", "url": "https://www.stocktitan.net/sec-filings/EVGN/6-k-evogene-ltd-current-report-foreign-issuer-219d7e68a823.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:09:43", "published_display": "16 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P.", "summary": "Evogene Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an at-the-market equity program for up to $2.93 million of its ordinary shares. This program offers the company financial flexibility but could dilute existing shareholders, with Evo", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVGN/pressreleases/2447885/evogene-sets-up-29-million-at-the-market-share-offering-with-agp/", "source_name": "The Globe and Mail", "published_at": "2026-06-15T07:39:17", "published_display": "15 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene to Present Its Pharma Division Achievements at the BIO International Convention", "summary": "Evogene Ltd. will present its pharma division's advancements at the BIO International Convention from June 22-25, 2026, in San Diego. Dr. Gabi Tarcic will highlight the company's AI-driven small-molecule discovery and optimization breakthroughs, particularly focusing on how ChemP", "url": "https://www.prnewswire.com/il/news-releases/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-302795111.html", "source_name": "PR Newswire", "published_at": "2026-06-12T12:11:26", "published_display": "12 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene enters sales agreement for at-the-market offering of up to $2.93 million", "summary": "Evogene Ltd. (NASDAQ:EVGN) has announced a sales agreement with A.G.P./Alliance Global Partners for an at-the-market (ATM) offering of up to $2.93 million in ordinary shares. This offering allows Evogene to sell shares periodically through the agent, with sales potentially occurr", "url": "https://ng.investing.com/news/sec-filings/evogene-enters-sales-agreement-for-atthemarket-offering-of-up-to-293-million-93CH-2554707", "source_name": "Investing.com Nigeria", "published_at": "2026-06-12T05:11:26", "published_display": "12 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQRzF1WDVVSW9Nb2xobjdlMko3elY5MjYxak1hUm5WX3hmOUNrVFVZTmp0RldEVm1xcHdVYlMwNWFnakZNeGJXUmEzbmpPWnhJWE5ocGhpZE1VdEFwbGZURTIzbl9JU0ZsR2d1bUNkekt2UEhxYUo1ZElMcFduN2V5Yk84NkwzWEJPU2p5OE16YmpyalU3MDdpT0hULWh2cTN2bVBxLU9mSzlNSDQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evogene-announces-successful-completion-phase-110000112.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Edges Lower, Testing Key Support at $0.66 - Motive Wave", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxORGIyMmhKNWJfVFdnYjc4YUNKWHZoRy13X3lxaVpZczlseklBRGpqaVppSTktUG43WFotZXBMeXphaE5ZS0hrNDBBSVhxX1BJY2tvQXgzamZSM2gyVFdfclZyZDhKaktjdlMxSFZ2bFpfTW9zVjI3T3J2Smp5NE9oUlV2dHROS3NvbVlOZlI4QXp4di03VDRXRA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level Test - Up Down Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPT09rNkFtYWFNeUNlVzZ0amd6Y0lNUC1DdmtDVFgxWDlFTU4wY0k4bUpTSG84eUpuZFFJRVQzX2cxcUoyTWdrOXVJYThhR2VHdXp3LTlKMzNFRXVVLXpORGdsMGZzXzVYZTZKb1k1eGVTaFhZQVdQa3NKTFc1SG8zem0zS3JsNzdjZVNHZ25kMW1icW1lM2VKRU9zTHRXVm0ycmc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/evogene-q1-earnings-snapshot-110635398.html", "source_name": "Associated Press", "published_at": "2026-05-20T11:06:35+00:00", "published_display": "20 May 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evogene-reports-first-quarter-2026-110000057.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQdTlMSDR4ekFTejZvMG5UNFAyN2dyR0hvaUZNMDdCd3NZSjRCMlFNTDNOenhtVUxQNl94UDAyeHBnaUttcVVvSEQwUDRyVXFjLU5Xd0hUZ0g2dl9YZVR2ZjNTbWNOal9UNk02NHZfaTk4SkYtVHZFYTlPQVY4c1kwMEQ0MEl2LWtqTUpoOS1qYnpyUmRodDNtWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUHpfbFFwZDh0R1V2TlAxZWQwalN2d0dCX1FxV0Z6ckdNblVXbzh5cnVXT2Y4OW84c21qRG11OVdnODlONkNra1AyemJHZFJZaGVKVzVTNDRYX3JhaGF1aFJ3UnQ1cUZfVVFFQzhGTW0yemI0R0dGQXZaSldtbUdWYkZ0cTJvcG1iYnc5dlBzaDY1R3NIbjAwV0ZGMXZ4M1cyTDF1MXRqY0c5dXlJTHg0eG9yUmhyQ3owbXFDTmM4cFFDZVU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOT1hsR1BGbVhxNjdLOXpMR0NmZnlNRXMxaXJzamFBcENPNFpEZFMwTlRJVTdKUEgtcVBiY0VJSm1MNHFvZFowdnMyX2hySDJtaHdmRWZiSS1RenlOQVFPZEFhSmtDOTB0WW1zTDY5aEhGem01eEFuWTlUc3pvNjNJRzB0YW9vSHhTU09pRE1XZDJkSkl0LTZqV2pNamZaQVBGN2c?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evogene (EVGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE82eG1uTFhnYXN4djA2ZVBHbC1ROEROWjd1eHVodGJNTXdnM055NlNqdm5memxXTXBvVkJhaFpLTmxlS0lSakFaV2djQjBGNFNfdFdv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:57:42+00:00", "published_display": "25 Apr 2025 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1CVzFpOVhQT1kwYXlSTnh4Q3ZscmNzeTNMUXpzTEZaWEpwODl4WUVqSng3MW1GQy1Pc25FS1pBYnJKcGo5VlRYM09uRjJXVDRkYW5XTThQVmRwNVBRNFBvQ1h3TU9NZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T16:46:43+00:00", "published_display": "11 May 2024 16:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVUVvekVCd3Jxb2ZFZDlaeG1WT19RQm9hMTdHYW1aVHZVR3ZGV2pGbENZZmhmMDU2cEF5aWZ4VXFYWFpwQThKTVBRR0Y4cW56bDB3V19ZMWNvZFlSUFJocnNiNklDaWx3UEF2S21uT05yRVJOdzllamQ0anhMTEdYc3NiTlpaLTZGZG53Sms1d3VjTm9OcmI3TFVWbTRsQ0xGRklHOGFFLUQ1SnNuZ3FHd3E3LW0yeU45?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:06:17+00:00", "published_display": "17 Jul 2026 20:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOMWJEcjRackctZVNtY3pma2xsZ3RTXzgxWW8tbjJGdTNqWDA3VlYtUFFMdWctOWFPOVZ2Um9QVWJCSWJQd1VoYWxoc1JsY3pjc1hjLTFpMnNsRUxiVTNhYmZSeHZuakc4MWdKeVpMd2FiaUhiaXlHcEY0anBpODVEODVIQ0RzSUFvRlpaVTFPNm1sSkpxQWVObGpoU1ZnUGpIOXFmZGQ0SGRraGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:03:43+00:00", "published_display": "17 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities", "summary": "AgPlenus, a subsidiary of Evogene Ltd., has introduced its Antifungal Potency Predictor (APP), a machine learning model designed to forecast the antifungal potency of small molecules from their chemical structures. This AI tool expands Evogene's ChemPass AI for Ag\u2122 platform, enab", "url": "https://igrownews.com/agplenus-latest-news/", "source_name": "iGrow News", "published_at": "2026-07-16T21:42:13", "published_display": "16 Jul 2026 21:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgPlenus AI Predicts Fungicide Potency Before Synthesis", "summary": "AgPlenus, a subsidiary of Evogene (NASDAQ: EVGN), has launched its Antifungal Potency Predictor (APP), a new machine learning model designed to forecast the antifungal potency of small molecules directly from their chemical structure. This expansion of the ChemPass AI for Ag\u2122 pla", "url": "https://www.stocktitan.net/news/EVGN/ag-plenus-launches-novel-ai-model-for-predicting-antifungal-potency-yuyrduwfmh4l.html", "source_name": "Stock Titan", "published_at": "2026-07-15T16:41:47", "published_display": "15 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag\u2122 Capabilities", "summary": "AgPlenus, a subsidiary of Evogene, announced the launch of its Antifungal Potency Predictor (APP), a new AI model designed to forecast the antifungal potency of small molecules earlier in the discovery process. This expansion amplifies the capabilities of Evogene's ChemPass AI fo", "url": "https://www.prnewswire.com/news-releases/agplenus-launches-novel-ai-model-for-predicting-antifungal-potency-expanding-chempass-ai-for-ag-capabilities-302826355.html", "source_name": "PR Newswire", "published_at": "2026-07-15T11:12:53", "published_display": "15 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake", "summary": "Kfir Silberman, through L.I.A. Pure Capital Ltd., has disclosed a 12.61% stake in Evogene Ltd. and is pushing for significant board changes. He has requested a special shareholder meeting to remove current board members (except Mr. Ofer Haviv), elect his nominees, and approve the", "url": "https://www.tradingview.com/news/tradingview:ca108cd6126e9:0-kfir-silberman-pushes-for-board-changes-at-evogene-with-12-61-stake/", "source_name": "TradingView", "published_at": "2026-07-10T13:40:28", "published_display": "10 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes", "summary": "Two Evogene Ltd. shareholders, L.I.A. Pure Capital Ltd. (12.61% stake) and Invest Pro Shukai Hon Ltd. (4.13% stake), are pushing for significant changes to Evogene's board of directors. They have formally demanded a special general meeting to remove most current directors, elect ", "url": "https://www.stocktitan.net/sec-filings/EVGN/schedule-13d-evogene-ltd-major-shareholder-acquisition-5-a7172c63292f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T13:40:24", "published_display": "10 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Partners with Tel Aviv University on AI Drug...", "summary": "Evogene, a computational chemistry company, is partnering with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to accelerate small-molecule drug discovery using Evogene's ChemPass AI platform. This collaboration, facilitated by Ramot, will combine AI-driven desig", "url": "https://allsci.com/news/licensing-deals/evogene-pairs-chempass-ai-with-tel-aviv-university-to-accelerate-academic-drug-discovery-pipeline/", "source_name": "AllSci", "published_at": "2026-07-09T15:09:09", "published_display": "09 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University launch drug discovery initiative", "summary": "Evogene and Tel Aviv University\u2019s Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate small-molecule drug discovery from Israeli academic research. The collaboration aims to overcome obstacles in early-stage drug development by combining Evogene's AI-based com", "url": "https://www.pharmaceutical-business-review.com/news/evogene-tel-aviv-university-drug-discovery/", "source_name": "Pharmaceutical Business review -", "published_at": "2026-07-09T09:41:13", "published_display": "09 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic biological insights and viable drug development program", "url": "https://www.sahmcapital.com/news/content/evogene-and-tel-aviv-universitys-blavatnik-center-for-drug-discovery-announce-joint-initiative-to-accelerate-ai-driven-small-molecule-drug-discovery-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-09T04:12:33", "published_display": "09 Jul 2026 04:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery", "summary": "Evogene Ltd. and the Blavatnik Center for Drug Discovery at Tel Aviv University have partnered in a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic research and drug candidate development by combin", "url": "https://www.marketscreener.com/news/evogene-ltd-and-blavatnik-center-for-drug-discovery-at-tel-aviv-university-announce-joint-initiativ-ce7f5ed9da8cf72d", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T16:40:21", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate AI-driven small-molecule drug discovery. This strategic initiative combines BCDD's experimental infrastructure with Evogene's ChemPass AI\u2122 generative engine to bridge the gap", "url": "https://www.biospectrumasia.com/news/34/27978/evogene-and-tel-aviv-university-to-accelerate-ai-driven-small-molecule-drug-discovery.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-08T13:50:31", "published_display": "08 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene partners with Tel Aviv University center on drug discovery", "summary": "Evogene Ltd. is collaborating with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to support small-molecule drug discovery projects from Israeli academic institutions. The partnership will combine Evogene\u2019s ChemPass AI computational chemistry platform with BCDD\u2019", "url": "https://www.investing.com/news/company-news/evogene-partners-with-tel-aviv-university-center-on-drug-discovery-93CH-4781318", "source_name": "Investing.com", "published_at": "2026-07-08T11:39:30", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene and Tel Aviv University team up to speed small-molecule drug discovery", "summary": "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The collaboration will integrate Evogene's ChemPass AI\u2122 platform with BCDD's experimental infrastructure under a Design-M", "url": "https://www.stocktitan.net/news/EVGN/evogene-and-tel-aviv-university-s-blavatnik-center-for-drug-itv9ae3rd68p.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Evogene is changing the future for the pharma and agriculture markets", "summary": "Evogene, a company founded in 2002, is leveraging its AI-driven computational platform, ChemPass AI\u2122, to revolutionize small molecule discovery for pharmaceutical and agricultural markets. By integrating AI, computational chemistry, biology, and data science, Evogene aims to acce", "url": "https://www.jpost.com/business-and-innovation/article-901580", "source_name": "The Jerusalem Post", "published_at": "2026-07-06T08:41:38", "published_display": "06 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene | 6-K: Report of foreign private issuer (related to financial reporting)", "summary": "This article is a 6-K filing by Evogene, which is a report for a foreign private issuer. These filings typically relate to financial reporting and other material information that needs to be disclosed to the SEC. Without the actual document, specific details are unavailable, but ", "url": "https://www.moomoo.com/news/notice/307351118/evogene-6-k-report-of-foreign-private-issuer-related-to", "source_name": "Moomoo", "published_at": "2026-06-26T23:39:35", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Evogene Ltd. \u2013 NASDAQ:EVGN", "summary": "This page displays the \"Price to book forward\" metric for Evogene Ltd. (NASDAQ: EVGN) on the TradingView platform. The content primarily shows navigation elements and general information about TradingView's offerings, but the specific financial data for EVGN is not visible.", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:17", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Evogene Ltd. \u2013 NASDAQ:EVGN", "summary": "This article displays the forward enterprise value to revenue for Evogene Ltd. (NASDAQ: EVGN). It is a financial data point presented by TradingView, with additional information provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:52", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd Actuals & Estimates (NASDAQ:EVGN)", "summary": "This article provides comprehensive financial data and analyst estimates for Evogene Ltd. (NASDAQ:EVGN), including its current stock price, historical performance, analyst forecasts, and detailed financial statements. It also covers Q3 earnings, revenue, net income, market capita", "url": "https://www.tradingview.com/symbols/NASDAQ-EVGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:09:52", "published_display": "25 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization", "summary": "Evogene Ltd. and Google Cloud have achieved a significant milestone in their collaboration, integrating agentic computational systems into Evogene's ChemPass AI platform. This advancement aims to accelerate small-molecule discovery and optimization by enabling early identificatio", "url": "https://www.marketscreener.com/news/evogene-ltd-and-google-cloud-announces-major-milestone-in-collaboration-advancing-chempass-ai-towar-ce7f5fd8df8df124", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T09:09:52", "published_display": "25 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI\u2122 Toward Autonomous Small Molecule Discovery and Optimization", "summary": "Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI\u2122 platform. This advancement aims to accelerate small-molecule discovery by enabling earlier identification of critical success criteria, ther", "url": "https://www.prnewswire.com/news-releases/evogene-announces-major-milestone-in-its-collaboration-with-google-cloud-advancing-chempass-ai-toward-autonomous-small-molecule-discovery-and-optimization-302808856.html", "source_name": "PR Newswire", "published_at": "2026-06-24T11:39:36", "published_display": "24 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene says Google Cloud AI can screen drug candidates earlier", "summary": "Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI\u2122 platform to enable earlier and deeper Target Product Profile (TPP) profiling for small-molecule discovery. This advancement aims to accelera", "url": "https://www.stocktitan.net/news/EVGN/evogene-announces-major-milestone-in-its-collaboration-with-google-h5guqfudklqg.html", "source_name": "Stock Titan", "published_at": "2026-06-24T02:10:39", "published_display": "24 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evogene Ltd (EVGN), highlighting major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in their positio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evgn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:00", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts project an average price target of $2.50, with one analyst recommending a \"Buy\" rating. The company's expected revenue for the next quarter is $3", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:40:00", "published_display": "17 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy", "summary": "Evogene (EVGN) outlined its ChemPass AI platform, which leverages generative AI to discover and optimize small molecules for both pharmaceutical and agricultural applications. The platform's tools, PointHit, ActiveSearch, and LeadOpGPT, are designed to screen vast molecular libra", "url": "https://www.stocktitan.net/sec-filings/EVGN/6-k-evogene-ltd-current-report-foreign-issuer-219d7e68a823.html", "source_name": "Stock Titan", "published_at": "2026-06-16T11:09:43", "published_display": "16 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P.", "summary": "Evogene Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an at-the-market equity program for up to $2.93 million of its ordinary shares. This program offers the company financial flexibility but could dilute existing shareholders, with Evo", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVGN/pressreleases/2447885/evogene-sets-up-29-million-at-the-market-share-offering-with-agp/", "source_name": "The Globe and Mail", "published_at": "2026-06-15T07:39:17", "published_display": "15 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene to Present Its Pharma Division Achievements at the BIO International Convention", "summary": "Evogene Ltd. will present its pharma division's advancements at the BIO International Convention from June 22-25, 2026, in San Diego. Dr. Gabi Tarcic will highlight the company's AI-driven small-molecule discovery and optimization breakthroughs, particularly focusing on how ChemP", "url": "https://www.prnewswire.com/il/news-releases/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-302795111.html", "source_name": "PR Newswire", "published_at": "2026-06-12T12:11:26", "published_display": "12 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene enters sales agreement for at-the-market offering of up to $2.93 million", "summary": "Evogene Ltd. (NASDAQ:EVGN) has announced a sales agreement with A.G.P./Alliance Global Partners for an at-the-market (ATM) offering of up to $2.93 million in ordinary shares. This offering allows Evogene to sell shares periodically through the agent, with sales potentially occurr", "url": "https://ng.investing.com/news/sec-filings/evogene-enters-sales-agreement-for-atthemarket-offering-of-up-to-293-million-93CH-2554707", "source_name": "Investing.com Nigeria", "published_at": "2026-06-12T05:11:26", "published_display": "12 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQRzF1WDVVSW9Nb2xobjdlMko3elY5MjYxak1hUm5WX3hmOUNrVFVZTmp0RldEVm1xcHdVYlMwNWFnakZNeGJXUmEzbmpPWnhJWE5ocGhpZE1VdEFwbGZURTIzbl9JU0ZsR2d1bUNkekt2UEhxYUo1ZElMcFduN2V5Yk84NkwzWEJPU2p5OE16YmpyalU3MDdpT0hULWh2cTN2bVBxLU9mSzlNSDQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evogene-announces-successful-completion-phase-110000112.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Edges Lower, Testing Key Support at $0.66 - Motive Wave", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxORGIyMmhKNWJfVFdnYjc4YUNKWHZoRy13X3lxaVpZczlseklBRGpqaVppSTktUG43WFotZXBMeXphaE5ZS0hrNDBBSVhxX1BJY2tvQXgzamZSM2gyVFdfclZyZDhKaktjdlMxSFZ2bFpfTW9zVjI3T3J2Smp5NE9oUlV2dHROS3NvbVlOZlI4QXp4di03VDRXRA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level Test - Up Down Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPT09rNkFtYWFNeUNlVzZ0amd6Y0lNUC1DdmtDVFgxWDlFTU4wY0k4bUpTSG84eUpuZFFJRVQzX2cxcUoyTWdrOXVJYThhR2VHdXp3LTlKMzNFRXVVLXpORGdsMGZzXzVYZTZKb1k1eGVTaFhZQVdQa3NKTFc1SG8zem0zS3JsNzdjZVNHZ25kMW1icW1lM2VKRU9zTHRXVm0ycmc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/evogene-q1-earnings-snapshot-110635398.html", "source_name": "Associated Press", "published_at": "2026-05-20T11:06:35+00:00", "published_display": "20 May 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evogene-reports-first-quarter-2026-110000057.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQdTlMSDR4ekFTejZvMG5UNFAyN2dyR0hvaUZNMDdCd3NZSjRCMlFNTDNOenhtVUxQNl94UDAyeHBnaUttcVVvSEQwUDRyVXFjLU5Xd0hUZ0g2dl9YZVR2ZjNTbWNOal9UNk02NHZfaTk4SkYtVHZFYTlPQVY4c1kwMEQ0MEl2LWtqTUpoOS1qYnpyUmRodDNtWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUHpfbFFwZDh0R1V2TlAxZWQwalN2d0dCX1FxV0Z6ckdNblVXbzh5cnVXT2Y4OW84c21qRG11OVdnODlONkNra1AyemJHZFJZaGVKVzVTNDRYX3JhaGF1aFJ3UnQ1cUZfVVFFQzhGTW0yemI0R0dGQXZaSldtbUdWYkZ0cTJvcG1iYnc5dlBzaDY1R3NIbjAwV0ZGMXZ4M1cyTDF1MXRqY0c5dXlJTHg0eG9yUmhyQ3owbXFDTmM4cFFDZVU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOT1hsR1BGbVhxNjdLOXpMR0NmZnlNRXMxaXJzamFBcENPNFpEZFMwTlRJVTdKUEgtcVBiY0VJSm1MNHFvZFowdnMyX2hySDJtaHdmRWZiSS1RenlOQVFPZEFhSmtDOTB0WW1zTDY5aEhGem01eEFuWTlUc3pvNjNJRzB0YW9vSHhTU09pRE1XZDJkSkl0LTZqV2pNamZaQVBGN2c?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE82eG1uTFhnYXN4djA2ZVBHbC1ROEROWjd1eHVodGJNTXdnM055NlNqdm5memxXTXBvVkJhaFpLTmxlS0lSakFaV2djQjBGNFNfdFdv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:57:42+00:00", "published_display": "25 Apr 2025 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evogene (EVGN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1CVzFpOVhQT1kwYXlSTnh4Q3ZscmNzeTNMUXpzTEZaWEpwODl4WUVqSng3MW1GQy1Pc25FS1pBYnJKcGo5VlRYM09uRjJXVDRkYW5XTThQVmRwNVBRNFBvQ1h3TU9NZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T16:46:43+00:00", "published_display": "11 May 2024 16:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 48, "sentiment_summary": {"positive": 17, "negative": 8, "neutral": 23, "score": 56, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 8.46, "count": 17}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 17, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 0.51, "latest_week": "2026-07-10", "one_week_move": 19.2, "four_week_move": -12.3, "twelve_week_move": -36.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.186053, "market_dynamics_buy_signal": false, "relative_strength": -55.975814, "fair_value_gap": -85.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.6881, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+19.2% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 8}, {"label": "PR Newswire", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "dars.gov.et", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 17}, {"label": "Guidance", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+19.2% over one week, -12.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M"}], "updated_at": "2026-07-17T23:57:13.454330+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}